IL6 and cardiac arrest: The IMICA Trial study (treatment effects of IL-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest) yielded significant results regarding the efficacy of monoclonal antibodies targeting IL-6 (tocilizumab) in mitigating the systemic inflammatory response as well as the extent of myocardial and cerebral damage in patients with cardiac arrest [89].